Wandercraft
15
7
7
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Exoskeleton Gait Training in Guillain-Barré Syndrome: Safety, Feasibility, Usability, and Longitudinal Outcomes
Role: collaborator
Self-balancing Personal Exoskeleton for SCI (WIP)
Role: lead
Self-balancing Personal Exoskeleton for SCI
Role: lead
Self-balancing Personal Exoskeleton for SCI (WINY)
Role: lead
Self-balancing Personal Exoskeleton for SCI (Site 2)
Role: lead
Safety and Feasibility of a Self-Balancing Exoskeleton for Rehabilitation in the Thoracic Surgical Intensive Care Unit: a Pilot Trial
Role: lead
Evaluation of Usability and Safety of the System Atalante in Patients With High Paraplegia and Tetraplegia
Role: lead
Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Subacute Phase (Month 1 to 4)
Role: lead
Human Factors Validation Testing of the Wandercraft Personal Exoskeleton
Role: lead
Evaluation of the Use of the Atalante System in Patients Presenting a Non-traumatic Hemiplegia in Acute-subacute Phase (15 Days to 6 Months).
Role: lead
Adherence to Long-term Exoskeleton Rehabilitation to Treat Lower Limb Weakness and / or Deficiencies in Adult Population
Role: lead
Assessment of the Interest of the Atalante Device for Patients With Manual Wheelchairs
Role: lead
Evaluation of the Use of the Atalante Exoskeleton in Patients Presenting an Hemiplegia Due to Cerebrovascular Accident
Role: lead
Atalante USAbility
Role: lead
Evaluation of Safety and Performance of the Atalante System With Patients With Lower Limb Paralysis
Role: lead
All 15 trials loaded